Ken Griffin Eye Point Pharmaceuticals, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 95,300 shares of EYPT stock, worth $763,353. This represents 0.0% of its overall portfolio holdings.
Number of Shares
95,300
Previous 498,800
80.89%
Holding current value
$763,353
Previous $11.5 Million
82.92%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding EYPT
# of Institutions
176Shares Held
53.9MCall Options Held
764KPut Options Held
1.57M-
Cormorant Asset Management, LP Boston, MA6.89MShares$55.2 Million8.2% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.76MShares$38.1 Million0.19% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.76MShares$30.1 Million3.33% of portfolio
-
Franklin Resources Inc San Mateo, CA3.39MShares$27.1 Million0.02% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$22.3 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $273M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...